The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | The evolving landscape of first-line therapies in advanced HCC
Mark Yarchoan, MD, Johns Hopkins University, Baltimore, MD, discusses the evolving landscape of first-line therapies in advanced hepatocellular carcinoma (HCC). Currently, durvalumab plus bevacizumab and atezolizumab plus bevacizumab are preferred regimens, with a potential third option being the IgG4, PD-1–directed monoclonal antibody camrelizumab in combination with the novel VEGFR2-directed tyrosine kinase inhibitor (TKI) rivoceranib, pending FDA approval. Additionally, the ongoing Phase III CheckMate 9DW (NCT04039607) trial comparing ipilimumab plus nivolumab to a tyrosine kinase inhibitor (TKI) might bring further changes to first-line options. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
